SCHEMBL4859896

SCHEMBL4859896

CC(c1ccccc1)n1c(-c2cnn(-c3ccccc3)c2)c([N+](=O)[O-])c(=O)n(C(C)c2ccccc2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.47
KDM5B Q9UGL1 2/20 0.40
DCTPP1 Q9H773 1/20 0.40
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
KDM5A P29375 1/20 0.38
CREBBP Q92793 3/20 0.36
GRM4 Q14833 6/20 0.36
ROCK2 O75116 1/20 0.35
HTR2B P41595 1/20 0.35
MTNR1A P48039 1/20 0.35
KCNH2 Q12809 1/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 2/20 0.35
HPGD P15428 2/20 0.35
CYP2C19 P33261 2/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868133 0.88 HSP90AA1 (0.43) HSP90AA1KDM5BDCTPP1ADORA2AADORA2B
SCHEMBL4859850 0.87 DCTPP1 (0.41) DCTPP1CREBBPROCK2ALDH1A1HPGD
SCHEMBL4864147 0.86 HSP90AA1 (0.41) HSP90AA1KDM5BDCTPP1ADORA2AADORA2B
SCHEMBL4862902 0.85 HSP90AA1 (0.47) HSP90AA1KDM5BADORA2AADORA2BADORA1
SCHEMBL4866206 0.85 HSP90AA1 (0.47) HSP90AA1KDM5BADORA2AADORA2BADORA1
SCHEMBL4762617 0.81 NPC1 (0.41) HSP90AA1DCTPP1MAPTSMN1; SMN2ALDH1A1
SCHEMBL4762612 0.81 NPC1 (0.41) HSP90AA1DCTPP1MAPTSMN1; SMN2ALDH1A1
SCHEMBL4866000 0.79 HSP90AA1 (0.47) HSP90AA1KDM5BADORA2AADORA2BADORA1
SCHEMBL4858900 0.79 ADORA2B (0.44) DCTPP1ADORA2AADORA2BADORA1CREBBP
SCHEMBL4917939 0.77 ADORA2B (0.46) DCTPP1ADORA2AADORA2BADORA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 HSP90AA1 1863/4885KDM5B 2051/4885DCTPP1 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.